Nlrp3 Inflammasome Activated Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: Microglia with active NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome, a key driver of neuroinflammation in Alzheimer's and Parkinson's diseases.
The NLRP3 inflammasome is a multimeric protein complex that activates caspase-1 and drives the maturation of pro-inflammatory cytokines IL-1β and IL-18. In microglia, NLRP3 activation represents a critical pathway linking protein aggregation (amyloid-beta, alpha-synuclein) to chronic neuroinflammation.
- NLRP3: Pattern recognition receptor
- ASC: Adaptor protein (PYCARD)
- Caspase-1: Protease (CASP1)
Pathogen-associated:
- LPS: Bacterial lipopolysaccharide
- ATP: Danger signal
- Nigericin: Bacterial toxin
Disease-associated:
- Amyloid-beta fibrils: Direct activation
- Alpha-synuclein oligomers: NLRP3 engagement
- Tau aggregates: TLR engagement
- Mitochondrial ROS: Oxidative stress
- Priming: NF-κB activation, NLRP3 transcription
- Activation: Assembly of NLRP3-ASC-caspase-1
- Cleavage: Pro-IL-1β, Pro-IL-18 processing
- Secretion: Inflammatory cytokine release
- Pyroptosis: Gasdermin D-mediated cell death
- Amyloid activates NLRP3: Direct microglial engagement
- IL-1β promotes tau: Kinase activation
- Chronic inflammation: Sustained cytokine production
- Cognitive decline: Correlates with progression
- Alpha-synuclein triggers: Inflammasome activation
- Dopaminergic toxicity: IL-1β mediated
- Microglial activation: Sustained inflammation
- Disease progression: NLRP3 correlates
- SOD1 models: NLRP3 activation
- TDP-43 pathology: Inflammasome engagement
- Motor neuron loss: Cytokine-mediated
- MCC950: Potent inhibitor, preclinical
- Dapansutrile (OLT1177): In clinical trials
- Dimethyl fumarate: Partial inhibition
- IL-1β blockade: Anakinra, canakinumab
- Caspase-1 inhibitors: VX-765
- Gasdermin D: Inhibitors in development
- Curcumin: NLRP3 modulation
- Resveratrol: SIRT1-mediated inhibition
- Quercetin: Anti-inflammatory effects
- IL-1β: Elevated in AD/PD
- IL-18: Disease severity correlate
- ASC specks: Inflammasome activity
- TSPO PET: Microglial activation
- MR spectroscopy: Inflammatory markers
- BV2 microglia: Murine cell line
- Primary microglia: Mouse and human
- iPSC-derived: Patient-specific
- NLRP3-/- mice: Knockout studies
- ASC-/- mice: Inflammasome deficiency
- Transgenic models: AD and PD
The study of Nlrp3 Inflammasome Activated Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- NLRP3 inflammasome in AD (2017)
- Alpha-synuclein and NLRP3 (2019)
- NLRP3 inhibitors for neurodegeneration (2021)
- Microglial inflammasome in PD (2020)